167 related articles for article (PubMed ID: 37499251)
1. Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
Aggarwal A; Taychert M; Hasanin L; Doll D; Basuino MG; Hasanein H
Oncology (Williston Park); 2023 Jul; 37(7):298-302. PubMed ID: 37499251
[TBL] [Abstract][Full Text] [Related]
2. Hypoalphalipoproteinemia and BRAF
Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
[TBL] [Abstract][Full Text] [Related]
4. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
[TBL] [Abstract][Full Text] [Related]
6. An effective treatment in Erdheim Chester disease: vemurafenib: a case report.
Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987
[TBL] [Abstract][Full Text] [Related]
7. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
[TBL] [Abstract][Full Text] [Related]
8. Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder.
Bosco J; Allende A; Varikatt W; Lee R; Stewart GJ
Intern Med J; 2015 Mar; 45(3):348-51. PubMed ID: 25735579
[TBL] [Abstract][Full Text] [Related]
9. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective.
Kanakis M; Petrou P; Lourida G; Georgalas I
Surv Ophthalmol; 2022; 67(2):388-410. PubMed ID: 34081930
[TBL] [Abstract][Full Text] [Related]
10. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.
Yuen CA; Bao S; Aung MS; Shishodia R; Kong XT
Per Med; 2024; 21(2):71-78. PubMed ID: 38275171
[TBL] [Abstract][Full Text] [Related]
11. Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Amoura Z
Blood; 2020 Apr; 135(16):1311-1318. PubMed ID: 32107533
[TBL] [Abstract][Full Text] [Related]
12. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.
Cohen Aubart F; Emile JF; Maksud P; Galanaud D; Cluzel P; Benameur N; Aumaitre O; Amoura Z; Haroche J
Br J Haematol; 2018 Jan; 180(1):150-153. PubMed ID: 27711968
[No Abstract] [Full Text] [Related]
14. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
[TBL] [Abstract][Full Text] [Related]
15. [Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].
Dasdelen S; Büschek F
Internist (Berl); 2020 Sep; 61(9):969-979. PubMed ID: 32785740
[TBL] [Abstract][Full Text] [Related]
16. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
18. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
Front Immunol; 2022; 13():918613. PubMed ID: 35874752
[TBL] [Abstract][Full Text] [Related]
19. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
[TBL] [Abstract][Full Text] [Related]
20. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
